After Flops, Ironwood Rebuilds It Pipeline With Liver Disease Deal

  • Ironwood Pharmaceuticals Inc IRWD has advanced plans to build its pipeline after securing a chance to license Cour Pharmaceuticals’ liver disease candidate CNP-104.
  • Having stopped the development of two prospects in quick succession, Ironwood began the year with a void where its pipeline used to be. 
  • Ironwood will pay Cour around $20 million in upfront and near-term fees associated with a Phase 1 trial of CNP-104. 
  • If Ironwood likes the Phase 1 data, it can license the drug in return for a financial package that could ultimately total $475 million.
  • The Company also posted Q3 revenues of $103.7 million, almost stagnant from a year ago, missing the consensus of $105.40 million.
  • Adjusted EPS of $0.33 came in ahead of the consensus of $0.31.
  • Total Linzess prescription demand in Q3 was 41 million capsules, +12% Y/Y.
  • Guidance: For FY21, Ironwood reaffirmed U.S. Linzess net sales growth of 6% - 8%. It expects revenue of $390 - $410 million (consensus of $408.1 million).
  • Price Action: IRWD shares closed down 2.10% at $12.58 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareContractsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!